Insights on Effective Complementary Strategies in the Management of Urinary Tract Infections
Abstract
Urinary tract infections (UTIs) are common health issues that occur frequently in both women and men. These infections occur in the urinary tract, leading to discomfort and potential complications. Prompt medical attention is essential to diagnose and treat UTIs effectively. Aim of this research was to provide an overview of effective complementary strategies in the management of UTIs. This review paper focuses on the current and future treatment strategies for UTI infections. Various natural remedies have been investigated as potential complementary therapies to enhance health outcomes for UTI patients. The efficacy of frequently employed natural products, including cranberry juice/extracts, ascorbic acid, hyaluronic acid, probiotics and multi-component formulations designed for the treatment and prevention of UTIs, has been explored. The probiotics serve to break down food and increase our immunity. Usually, multiple doses of antibiotics are used to treat these infections, but there are many side effects and bacterial resistance rates are increasing. Complementary UTI management strategies, including effective dietary regimens and new formulations, are attaining approvals. Drinking liquids daily significantly suppresses UTI infections. Incorporating daily consumption of cranberry juice may still be regarded as a viable complementary strategy to aid in the management of UTI infections.
References
Hudson RE, Job KM, Sayre CL, Krepkova LV, Sherwin CM, Enioutina EY. Examination of complementary medicine for treating urinary tract infections among pregnant women and children. Front Pharmacol. 2022 Apr 27;13:883216. doi: 10.3389/fphar.2022.883216.
Reid G. Potential preventive strategies and therapies in urinary tract infection. World J Urol. 1999;17:359-63. doi: 10.1007/s003450050161.
Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison’s principles of internal medicine. In: Harrison’s principles of internal medicine-15th edition. New York: McGraw-Hill; 2001. pp. 1187-1187.
Sheerin NS, Glover EK. Urinary tract infection. Medicine. 2019;47(9):546-50. doi: 10.1016/j.mpmed.2019.06.008.
Bhise SB. Human anatomy and physiology. Pune, India: Pragati Books; 2008.
Mohan H. Textbook of pathology. New Delhi, India: Jaypee Brothers Medical Publishers; 2018.
Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrobl Agents Chemother. 2010;54(9):4006-8. doi: 10.1128/aac.01760-09.
Blumberg JB, Camesano TA, Cassidy A, Kris-Etherton P, Howell A, Manach C, et al. Cranberries and their bioactive constituents in human health. Adv Nutr. 2013;4(6):618-32. doi: 10.3945%2Fan.113.004473.
Haverkorn MJ, Mandigers J. Reduction of bacteriuria and pyuria using cranberry juice. JAMA. 1994;272(8):590. doi: 10.1001/jama.272.8.590a.
Kahn HD, Panariello VA, Saeli J, Sampson JR, Schwartz E. Effect of cranberry juice on urine. J Am Diet Assoc. 1967 Sep;51(3):251-4. PMID: 6035629.
Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry. 2005;66(18):2281-91. doi: 10.1016/j.phytochem.2005.05.022.
Lynch DM. Cranberry for prevention of urinary tract infections. Am Fam Physician. 2004 Dec 1;70(11):2175-7. PMID: 15606066.
Schmidt DR, Sobota AE. An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates. Microbios. 1988;55(224-225):173-81. PMID: 3063927.
Sobota AE. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J Urol. 1984;131(5):1013-6. doi: 10.1016/S0022-5347(17)50751-X.
Ermel G, Georgeault S, Inisan C, Besnard M. Inhibition of adhesion of uropathogenic Escherichia coli bacteria to uroepithelial cells by extracts from cranberry. J Med Food. 2012 Feb;15(2):126-34. doi: 10.1089/jmf.2010.0312.
Liu H, Howell AB, Zhang DJ, Khoo C. A randomized, double-blind, placebo-controlled pilot study to assess bacterial anti-adhesive activity in human urine following consumption of a cranberry supplement. Food Funct. 2019;10(12):7645-52. doi: 10.1039/C9FO01198F.
Rafsanjany N, Senker J, Brandt S, Dobrindt U, Hensel A. In vivo consumption of cranberry exerts ex vivo antiadhesive activity against FimH-dominated uropathogenic Escherichia coli: A combined in vivo, ex vivo, and in vitro study of an extract from Vaccinium macrocarpon. J Agric Food Chem. 2015;63(40):8804-18. doi: 10.1021/acs.jafc.5b03030.
Chan M, Hidalgo G, Asadishad B, Almeida S, Muja N, Mohammadi MS, et al. Inhibition of bacterial motility and spreading via release of cranberry derived materials from silicone substrates. Colloids Surf B Biointerfaces. 2013;110:275-80. doi: 10.1016/j.colsurfb.2013.03.047.
Rodríguez-Pérez C, Quirantes-Piné R, Uberos J, Jiménez-Sánchez C, Peña A, Segura-Carretero A. Antibacterial activity of isolated phenolic compounds from cranberry (Vaccinium macrocarpon) against Escherichia coli. Food Funct. 2016 Mar;7(3):1564-73. doi: 10.1039/c5fo01441g.
Ulrey RK, Barksdale SM, Zhou W, van Hoek ML. Cranberry proanthocyanidins have anti-biofilm properties against Pseudomonas aeruginosa. BMC Complement Altern Med. 2014 Dec 16;14:499. doi: 10.1186/1472-6882-14-499.
Wojnicz D, Tichaczek-Goska D, Korzekwa K, Kicia M, Hendrich AB. Study of the impact of cranberry extract on the virulence factors and biofilm formation by Enterococcus faecalis strains isolated from urinary tract infections Int J Food Sci Nutr. 2016 Nov 16;67(8):1005-16. doi: 10.1080/09637486.2016.1211996.
Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study. Int Urol Nephrol. 2016 Sep;48:1379-86. doi:10.1007/s11255-016-1342-8.
Salo J, Uhari M, Helminen M, Korppi M, Nieminen T, Pokka T, Kontiokari T. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized placebo-controlled trial. Clin Infect Dis. 2012 Feb 1;54(3):340-6. doi:10.1093/cid/cir801.
Foxman B, Cronenwett AE, Spino C, Berger MB, Morgan DM. Cranberry juice capsules and urinary tract infection after surgery: results of a randomized trial. Am J Obstet Gynecol. 2015 Aug 1;213(2):194-e1. doi:10.1016/j.ajog.2015.04.003.
Cimolai N, Cimolai T. The cranberry and the urinary tract. Eur J Clin Microbiol Infect Dis. 2007 Nov;26:767-76. doi:10.1007/s10096-007-0379-0.
Guay DR. Cranberry and urinary tract infections. Drugs. 2009 May;69:775-807. doi:10.2165/00003495-200969070-00002.
Shmuely H, Ofek I, Weiss EI, Rones Z, Houri-Haddad Y. Cranberry components for the therapy of infectious disease. Curr Opin Biotechnol. 2012 Apr 1;23(2):148-52. doi:10.1016/j.copbio.2011.10.009.
Maki KC, Kaspar KL, Khoo C, Derrig LH, Schild AL, Gupta K. Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection. Am J Clin Nutr. 2016 Jun 1;103(6):1434-42. doi:10.3945/ajcn.116.130542.
Takahashi S, Hamasuna R, Yasuda M, Arakawa S, Tanaka K, Ishikawa K, et al. A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. J Infect Chemother. 2013 Jan 1;19(1):112-7. doi:10.1007/s10156-012-0467-7.
Stapleton AE, Dziura J, Hooton TM, Cox ME, Yarova-Yarovaya Y, Chen S, et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc. 2012;87(2):143-50. doi:10.1016/j.mayocp.2011.10.006.
Vostalova J, Vidlar A, Simanek V, Galandakova A, Kosina P, Vacek J, et al. Are high proanthocyanidins key to cranberry efficacy in the prevention of recurrent urinary tract infection?. Phytother Res. 2015 Oct;29(10):1559-67. doi:10.1002/ptr.5427.
YarnellE.Botanical medicines for the urinary tract. World J Urol. 2002 Nov;20:285-93. doi:10.1007/s00345-002-0293-0.
Yilmaz A, Bahat E, Yilmaz GG, Hasanoglu A, Akman S, Guven AG. Adjuvant effect of vitamin A on recurrent lower urinary tract infections. Pediatr Int. 2007 Jun;49(3):310-3. doi:10.1111/j.1442-200X.2007.02370.x.
Fazly Bazzaz BS, Darvishi Fork S, Ahmadi R, Khameneh B. Deep insights into urinary tract infections and effective natural remedies. Afr J Urol. 2021 Dec;27:1-3. doi:10.1186/s12301-020-00111-z.
Romm A. Botanical medicine for women's health e-book: botanical medicine for women's health e-book. Amsterdam, Netherlands: Elsevier Health Sciences; 2017.
Head KA. Natural approaches to prevention and treatment of infections of the lower urinary tract. Altern Med Rev. 2008 Sep;13(3):227-44. PMID: 18950249.
Wendakoon CN, Sakaguchi M. Inhibition of amino acid decarboxylase activity of Enterobacter aerogenes by active components in spices. J Food Prot. 1995 Mar 1;58(3):280-3. doi:10.4315/0362-028X-58.3.280.
Amalaradjou MA, Venkitanarayanan K. Natural approaches for controlling urinary tract infections. Urinary Tract Infect. 2011 Oct 3;13:227-44. doi:10.5772/25079.
Narayanan A, Muyyarikkandy MS, Mooyottu S, Venkitanarayanan K, Amalaradjou MA. Oral supplementation of trans‐cinnamaldehyde reduces uropathogenic Escherichia coli colonization in a mouse model. Lett Appl Microbiol. 2017 Mar 1;64(3):192-7. doi:10.1111/lam.12713.
Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr. 2006 Mar 1;136(3):716S-25S. doi:10.1093/jn/136.3.716s.
Lionel OO, Adegboyega IP, Ezekiel AO, Olufunke BC. Antimicrobial activity of garlic (Allium sativum) on selected uropathogens from cases of urinary tract infection. Ann Trop Pathol. 2020 Jul 1;11(2):133-8. doi:10.4103/atp.atp_9_20.
Harjai K, Kumar R, Singh S. Garlic blocks quorum sensing and attenuates the virulence of Pseudomonas aeruginosa. FEMS Immunol Med Microbiol. 2010 Mar 1;58(2):161-8. doi:10.1111/j.1574-695X.2009.00614.x.
Chang Z, An L, He Z, Zhang Y, Li S, Lei M, et al. Allicin suppressed Escherichia coli-induced urinary tract infections by a novel MALT1/NF-κB pathway. Food Funct. 2022;13(6):3495-511. doi: 10.1039/D1FO03853B.
Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers. 2018 Jun 25;10(7):701. doi:10.3390/polym10070701.
Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: molecular mechanisms and therapeutic trajectory. Front Vet Sci. 2019 Jun 25;6:458280. doi:10.3389/fvets.2019.00192.
Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol. 1996 Jul;156(1):45-8. doi:10.1016/S0022-5347(01)65933-0.
Necas JB, Bartosikova L, Brauner P, Kolar JJ. Hyaluronic acid (hyaluronan): a review. Vet Med. 2008 Aug 31;53(8):397-411. doi:10.17221/1930-VETMED.
Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol. 2007 Jun 1;51(6):1534-41. doi:10.1016/j.eururo.2007.03.020.
Lee DG, Cho JJ, Park HK, Kim DK, Kim JI, Chang SG, Lee SJ. Preventive effects of hyaluronic acid on Escherichia coli-induced urinary tract infection in rat. Urology. 2010 Apr 1;75(4):949-54. doi:10.1016/j.urology.2009.05.047.
Lee SJ, Son KH, Chang HW, Do JC, Jung KY, Kang SS, Kim HP. Antiinflammatory activity of naturally occurring flavone and flavonol glycosides. Arch Pharm Res. 1993 Mar;16:25-8. doi:10.1007/BF02974123.
Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018 Dec;15(12):750-76. doi:10.1038/s41585-018-0106-x.
Howell AB, Foxman B. Cranberry juice and adhesion of antibiotic-resistant uropathogens. Jama. 2002 Jun 19;287(23):3082-3. doi:10.1001/jama.287.23.3077.
Batoei S, Mahboubi M, Yari R. Antibacterial activity of Tribulus terrestris methanol extract against clinical isolates of Escherichia coli. Herba polonica. 2016;62(2):57-66. doi:10.1515/hepo-2016-0011.
Amalaradjou MA, Narayanan A, Baskaran SA, Venkitanarayanan K. Antibiofilm effect of trans-cinnamaldehyde on uropathogenic Escherichia coli. J Urol. 2010 Jul;184(1):358-63. doi:10.1016/j.juro.2010.03.006.
Kreydiyyeh SI, Usta J. Diuretic effect and mechanism of action of parsley. J Ethnopharmacol. 2002 Mar 1;79(3):353-7. doi: 10.1016/S0378-8741(01)00408-1.
Pepeljnjak S, Kosalec I, Kalodera Z, Blazević N. Antimicrobial activity of juniper berry essential oil (Juniperus communis L., Cupressaceae). Acta Pharm. 2005 Dec;55(4):417-22. PMID: 16375831.
Sahoo S, Kar DM, Mohapatra S, Rout SP, Dash SK. Antibacterial Activity of Hybanthus enneaspermus Against Selected Urinary Tract Pathogens. Indian J Pharm Sci. 2006 Sep 1;68(5). doi: 10.4103/0250-474X.29640.
Oladosu SA, Coker AO, Nwaokorie F, Olaniran O, Olawale JT, Oyetoke OO, Awoyeni EA. Antibacterial effects of Phyllantus amarus on urinary tract pathogens. Int Clin Pathol J. 2019;7:1-0. doi:10.15406/icpjl.2019.07.0019.
Hossan S, Hanif A, Agarwala B, Sarwar S, Karim M, Taufiq-Ur-Rahman M, et al. Traditional use of medicinal plants in Bangladesh to treat urinary tract infections and sexually transmitted diseases. Ethnobot Res Appl 2010;8:061-74. doi: 10.17348/era.8.0.61-74.
Kreft S, Lunder M. Herbal medicinal products for the treatment of the urogenital infection. Farm Vestn. 2011;62:87-95.
Mutters NT, Mampel A, Kropidlowski R, Biehler K, Günther F, Bălu I, Malek V, Frank U. Treating urinary tract infections due to MDR E. coli with Isothiocyanates–a phytotherapeutic alternative to antibiotics. Fitoterapia. 2018 Sep 1;129:237-40. doi: 10.1016/j.fitote.2018.07.012.
Rafsanjany N, Lechtenberg M, Petereit F, Hensel A. Antiadhesion as a functional concept for protection against uropathogenic Escherichia coli: in vitro studies with traditionally used plants with antiadhesive activity against uropathognic Escherichia coli. J Ethnopharmacol. 2013 Jan 30;145(2):591-7. doi: 10.1016/j.jep.2012.11.035.
Maurya SK, Singh AK. Clinical efficacy of Moringa oleifera Lam. stems bark in urinary tract infections. International scholarly research notices. 2014;2014(1):906843.
Tariq AL, Reyaz AL. Terminalia chebula: a treatment against pathogenic Proteus vulgaris strains associated with urinary tract infection. Int J Res Ayurveda Pharm 2013;4(4). doi:10.7897/2277-4343.04422.
Sharma A, Chandraker S, Patel VK, Ramteke P. Antibacterial activity of medicinal plants against pathogens causing complicated urinary tract infections. Indian J Pharm Sci. 2009 Mar;71(2):136. doi: 10.4103%2F0250-474X.54279.
Anukam KC, Reid G. Probiotics: 100 years (1907–2007) after Elie Metchnikoff’s observation. Communicating current research and educational topics and trends in applied microbiology. 2007;1:466-74.
Das S. Natural therapeutics for urinary tract infections—a review. Futur J Pharm Sci. 2020 Sep 18;6(1):64. doi: 10.1186/s43094-020-00086-2.
Hanson L, VandeVusse L, Jermé M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: a systematic review. J Midwifery Womens Health. 2016 May;61(3):339-55. doi: 10.1111/jmwh.12472.
Beerepoot MA, Stobberingh EE, Geerlings SE. [A study of non-antibiotic versus antibiotic prophylaxis for recurrent urinary-tract infections in women (the NAPRUTI study)]. Ned Tijdschr Geneeskd. 2006 Mar 11;150(10):574-5. Dutch. PMID: 16566424.
Costantini E, Giannitsas K, Illiano E. The role of nonantibiotic treatment of community-acquired urinary tract infections. Curr Opin Urol. 2017 Mar 1;27(2):120-6. doi: 10.1097/MOU.0000000000000366.
Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs. 2006 Jun;66:1253-61. doi: 10.2165/00003495-200666090-00007.
Ghartey JP, Smith BC, Chen Z, Buckley N, Lo Y, Ratner AJ, et al. Lactobacillus crispatus dominant vaginal microbiome is associated with inhibitory activity of female genital tract secretions against Escherichia coli. PloS one. 2014 May 7;9(5):e96659. doi:10.1371/journal.pone.0096659.
Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents. 2006 Aug 1;28:30-4. doi:10.1016/j.ijantimicag.2006.05.008.
Beerepoot MA, Geerlings SV, Van Haarst EP, Van Charante NM, Ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013 Dec 1;190(6):1981-9. doi: 10.1016/j.juro.2013.04.142.
Grin PM, Kowalewska PM, Alhazzan W, Fox-Robichaud AE. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol. 2013 Feb;20(1):6607-14. PMID: 23433130.
Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011 May 15;52(10):1212-7. doi:10.1093/cid/cir183.
Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al. Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence or urinary tract infections. FEMS Immunol Med Microbiol. 2003;35(2):131. doi:10.1016/S0928-8244(02)00465-0.
Abdulwahab M, Abdulazim A, Nada MG, Radi NA. A study on the inhibitory effect of vaginal lactobacilli on uropathogenic Escherichia coli. Life Sci J. 2013;10(2):773-8.
Carlsson S, Govoni M, Wiklund NP, Weitzberg E, Lundberg JO. In vitro evaluation of a new treatment for urinary tract infections caused by nitrate-reducing bacteria. Antimicrob Agents Chemother. 2003 Dec;47(12):3713-8. doi: 10.1128/aac.47.12.3713-3718.2003.
Carlsson S, Wiklund NP, Engstrand L, Weitzberg EA, Lundberg JO. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric oxide. 2001 Dec 1;5(6):580-6. doi:10.1006/niox.2001.0371.
Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V. Effectiveness of a combination of cranberries, Lactobacillus rhamnosus, and vitamin C for the management of recurrent urinary tract infections in women: results of a pilot study. Eur Urol. 2016 Dec 1;70(6):912-5. doi: 10.1016/j.eururo.2016.05.042.
Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, Velasco R, Trujillo-Hernández B, Vásquez C. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007 Jan 1;86(7):783-7. doi:10.1080/00016340701273189.
Yousefichaijan P, Goudarzi AA, Rezagholizamenjany M, Kahbazi M, Rafeie M, Shabestari AA, et al. Efficacy of ascorbic acid supplementation in relief of symptoms due to febrile upper urinary tract infection in children, a clinical trial and hospital based study. Arch Pediatr Infect Dis. 2018 Oct 31;6(4):e57071. doi:10.5812/pedinfect.57071.
Kahbazi M, Sharafkhah M, Yousefichaijan P, Taherahmadi H, Rafiei M, Kaviani P, et al. Vitamin A supplementation is effective for improving the clinical symptoms of urinary tract infections and reducing renal scarring in girls with acute pyelonephritis: a randomized, double-blind placebo-controlled, clinical trial study. Complement Ther Med. 2019 Feb 1;42:429-37. doi: 10.1016/j.ctim.2018.12.007.
Hertting O, Lüthje P, Sullivan D, Aspenström P, Brauner A. Vitamin D-deficient mice have more invasive urinary tract infection. PLoS One. 2017 Jul 27;12(7):e0180810. doi: 10.1371/journal.pone.0180810.
Ramos NL, Sekikubo M, Kironde F, Mirembe F, Sääf M, Brauner A. The impact of vitamin D on the innate immune response to uropathogenic Escherichia coli during pregnancy. Clin Microbiol Infect. 2015 May 1;21(5):482-e1. doi: 10.1016/j.cmi.2014.12.010.
Georgieva V, Kamolvit W, Herthelius M, Lüthje P, Brauner A, Chromek M. Association between vitamin D, antimicrobial peptides and urinary tract infection in infants and young children. Acta Paediatr. 2019 Mar;108(3):551-6. doi:10.1111/apa.14499.
Jorde R, Sollid ST, Svartberg J, Joakimsen RM, Grimnes G, Hutchinson MY. Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects. Infect Dis. 2016 Dec 1;48(11-12):823-8. doi: 10.1080/23744235.2016.1201853.
Strassner C, Friesen A. [Therapy of candiduria by alkalinization of urine. Oral treatment with potassium-sodium-hydrogen citrate]. Fortschr Med. 1995 Sep 10;113(25):359-62. German. PMID: 7498850.
Spooner JB. Alkalinisation in the management of cystitis. J Int Med Res. 1984 Jan;12(1):30-4. doi: 10.1177/030006058401200105.
Hu X, Shi Y, Zhang P, Miao M, Zhang T, Jiang B. D‐Mannose: Properties, production, and applications: An overview. Compr Rev Food Sci Food Saf. 2016 Jul;15(4):773-85. doi: 10.1111/1541-4337.12211.
Brument S, Sivignon A, Dumych TI, Moreau N, Roos G, Guerardel Y, et al. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn’s disease patients. J Med Chem. 2013 Jul 11;56(13):5395-406. doi: 10.1021/jm400723n.
Duncan D. Alternative to antibiotics for managing asymptomatic and non-symptomatic bacteriuria in older persons: a review. Br J Community Nurs. 2019 Mar 2;24(3):116-9. doi: 10.12968/bjcn.2019.24.3.116.
Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Efficacy of combined antibacterial-prebiotic therapy in combination with D-mannose in women with uncomplicated lower urinary tract infection. Urologiia. 2019 Dec 15(6):38-43. doi: 10.18565/urology.2019.6.38-43.
Scribano D, Sarshar M, Prezioso C, Lucarelli M, Angeloni A, Zagaglia C, et al. D-Mannose treatment neither affects uropathogenic Escherichia coli properties nor induces stable FIMH modifications. Molecules. 2020 Jan 13;25(2):316. doi:10.3390/molecules25020316.
Schaeffer AJ. Infection and inflammation of the genitourinary tract. J Urol. 2002 Apr;167(4):1926-35. doi:10.1016/S0022-5347(05)65261-5.
Wellens A, Garofalo C, Nguyen H, Van Gerven N, Slättegård R, Hernalsteens JP, et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH–oligomannose-3 complex. PLoS one. 2008 Apr 30;3(4):e2040. doi: 10.1371/journal.pone.0002040.
Russo E, Montt Guevara M, Giannini A, Mannella P, Palla G, Caretto M, et al. Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery. Climacteric. 2020 Mar 3;23(2):201-5. doi: 10.1080/13697137.2019.1679110.
Kyriakides R, Jones P, Somani BK. Role of D-mannose in the prevention of recurrent urinary tract infections: evidence from a systematic review of the literature. Eur Urol Focus. 2021 Sep 1;7(5):1166-9. doi: 10.1016/j.euf.2020.09.004.
Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020 Aug 1;223(2):265-e1. doi: 10.1016/j.ajog.2020.05.048.
Domenici L, Monti M, Bracchi C, Giorgini M, Colagiovanni V, Muzii L, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2920-5. PMID: 27424995.
Porru D, Parmigiani A, Tinelli C, Barletta D, Choussos D, Di Franco C, et al. Oral D-mannose in recurrent urinary tract infections in women: A pilot study. J Clin Urol. 2014 May;7(3):208-13. doi: 10.1177/2051415813518332.
Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32:79-84. doi: 10.1007/s00345-013-1091-6.
Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem. 2010 Dec 23;53(24):8627-41. doi: 10.1021/jm101011y.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).